Role
Frederick Frank is a partner and Vice Chairman of Peter J. Solomon Company, a member of its Mergers and Acquisitions Group and with Managing Director Mary Tanner, co-heads PJSC’s global pharmaceutical and life sciences practice.
Experience
Mr. Frank joined the firm in 2009 from Barclays Capital where he was Vice Chairman. He began his investment banking career at Smith, Barney & Co. Inc. in 1958, where he attained the positions of Co-Head of Research, Vice President and Director. Subsequently he joined Lehman Brothers, Inc., in 1969, as a partner. At Lehman, Mr. Frank provided investment banking services to an extensive number of companies in the pharmaceutical, biotechnology, healthcare services, medical device and nutraceutical industries, and was involved in hundreds of financings, strategic alliances and merger and acquisition transactions in the global healthcare industry.
To follow an interesting global thread, Mr. Frank’s clients have included: Marion Laboratories, from leading the company’s initial public offering to its acquisition of the pharmaceutical division of Dow Chemical, creating Marion Merrill Dow. Then with Mary Tanner, he represented Marion Merrill Dow in creating its merger with Hoechst to form Hoechst Marion Roussel, Inc. Mr. Frank also represented Synthelabo in France in its acquisition by Sanofi which created the second largest French pharmaceutical company. In addition, Mr. Frank represented Genetech commencing in 1995 with the purchase of a controlling interest by Roche and in its 1999 extension & modification.
Most recently, Mr. Frank advised CV Therapeutics Inc in its $l.4B sale to Gilead Sciences Inc.; BioDuro LLC, a China-based company in its sale to PPD, Inc.; TargeGen, Inc., in its sale to Sanofi-Aventis; CGI Pharmaceuticals, Inc. in its sale to Gilead Sciences, Inc. and OSI Pharmaceuticals Inc. in its sale to Astellas Pharma Inc.
A frequent guest speaker at industry conferences, Mr. Frank and Ms. Tanner co-chaired the 2011 Yale University Drug Discovery Symposium: The Changing Role of Academia in Drug Discovery and Development.
Professional Affiliations
- Director, Landec Corporation
- Director, PDL Biosciences, Inc.
Previous Professional Affiliations
- Former Director, The Institute for Systems Biology
- Former Director, Pharmaceutical Product Development, Inc.
- Former Director, Diagnostic Products
Not-For-Profit Affiliations
- Chairman, National Genetics Foundation
- Member, Advisory Board, Yale School of Organization and Management
- Member, Advisory Board, Harvard School of Public Health
- Member, Advisory Board, Massachusetts Institute of Technology Center for Biomedical Innovation
- Trustee Emeritus, The Hotchkiss School
- Former Member, Advisor, Johns Hopkins School of Public Health
Honors
- 2011 – Pharmaceutical Executive Magazine: "30 Made a Difference"
- 2009 – Life Time Achievement Award, Jennifer Diamond Cancer Foundation
- 2007 – American Liver Foundation – Award for Excellence
- 2007 – Reed Elsevier – The Top 100 Living Contributors to Biotechnology
- 2006 – Gilda’s Club of New York City – Visionary Award
- 2004 – Weizmann Institute of Science – The Albert Einstein Award
- 1997 – Biotech Meeting at Laguna Niguel - Hall of Fame Award for Special Recognition for an Individual
Academic Credentials
Mr. Frank received an M.B.A. from Stanford University and a B.A. from Yale University. He is also a Chartered Financial Analyst: CFA Degree.